{"title": "Merck to Initiate Proof-of-Concept Study of Posaconazole for Chronic Chagas Disease, Recognized by WHO as One of the World", "author": null, "url": "https://www.fiercepharma.com/pharma/merck-to-initiate-proof-of-concept-study-of-posaconazole-for-chronic-chagas-disease", "hostname": "fiercepharma.com", "description": "WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- Merck today announced plans to initiate a Phase II investigational proof-of-concept clinical study to evaluate its oral antifungal agent posaconazole for | WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- Merck today announced plans to initiate a Phase II investigational proof-of-concept clinical study to evaluate its oral antifungal agent posaconazole for", "sitename": "FiercePharma", "date": "2010-06-24", "cleaned_text": "Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Subscribe Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us "}